CareDx posts Q3 2026 earnings, lifts full‑year revenue outlook to $520‑$530 million
CareDx reported third‑quarter 2026 revenue of $139 million, a 39% year‑over‑year increase, driven by strong testing‑services growth. The company raised its full‑year 2026 revenue guidance to a range of $520 million‑$530 million and increased its adjusted EBITDA outlook. Management highlighted progress on its specialty‑oncology platform and pipeline launches slated for 2027.
Why it matters
The higher revenue guidance expands analysts’ revenue forecasts for 2026, implying stronger top‑line growth than previously expected. The raised adjusted EBITDA range suggests improved profitability, which may affect valuation models and target‑price calculations.
Key facts
- 1Q3 2026 revenue was $139 million, up 39% year‑over‑year. stocktitan.net
- 2Testing‑services revenue was $119 million, up 65% year‑over‑year. stocktitan.net
- 3GAAP net income for the quarter was $2 million. stocktitan.net
- 4Adjusted EBITDA for the quarter was $15 million, compared with $30 million in Q3 2025. stocktitan.net
- 5Full‑year 2026 revenue guidance was raised to $520 million‑$530 million. stocktitan.net
- 6Adjusted EBITDA guidance for 2026 was increased to $90 million‑$100 million. finance.yahoo.com
Open questions
- Adjusted EBITDA for Q3 2026 is reported as $15 million and $30 million on the same GAAP basis.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.